Rct Evidence

In GLORY-1, mazdutide 6 mg produced mean body-weight change of approximately negative 15 percent versus negative 0.5 percent with placebo at 48 weeks. The placebo-subtracted treatment difference was approximately negative 14 percentage points. Orforglipron 36 mg achieved approximately negative 12 percent at 72 weeks in ATTAIN-1 but no head-to-head RCT between the two agents exists.

Yes. The EECOH-2 phase 3 trial demonstrated that once-weekly ecnoglutide at both tested doses was non-inferior to dulaglutide in HbA1c reduction over 52 weeks, with the higher dose achieving superiority. The gastrointestinal adverse-event profile was mild-to-moderate and did not exceed dulaglutide rates.

The Phase 3 LUCIDITY trial (NCT06747468), with topline data announced August 18, 2026, showed that avexitide — a first-in-class GLP-1 receptor antagonist — reduced the composite rate of Level 2 and Level 3 hypoglycemic events by 55% versus placebo (p=0.000003) over 16 weeks in adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass. Amylyx plans an NDA by end of 2026.

The TRIUMPH-1 topline readout — the primary obesity-without-diabetes arm of retatrutide's phase III programme — reports mean body-weight reductions of approximately 19% at 4 mg, 24% at 8 mg, and 28% at 12 mg over 80 weeks versus placebo. Cardiometabolic endpoints show dose-proportional improvements. The 80-week timepoint is the longest placebo-controlled pharmacological weight-loss dataset for any triple agonist in 2026.

As of 2026, oral GLP-1 receptor agonism has Phase 3 RCT evidence supporting its efficacy in obesity. Oral semaglutide 50 mg achieves 15 to 17 percent body-weight reduction, matching the 14·9 percent benchmark of subcutaneous semaglutide 2·4 mg, while orforglipron reached approximately 16 percent in Phase 3 ATTAIN-1. Neither oral agent has matched tirzepatide's approximately 20 percent ceiling.

As of mid-2026, retatrutide's TRIUMPH phase 3 programme has delivered 72-week data confirming weight reductions exceeding 20% at the 12 mg dose — the largest placebo-controlled pharmacological weight-loss signal in a completed RCT. Cardiometabolic endpoints show meaningful improvements in blood pressure, triglycerides, and glycaemic markers. Dose-limiting adverse events are predominantly gastrointestinal and concentrated in the escalation phase.

The 2025 SURMOUNT-5 RCT established that tirzepatide produced approximately 20% mean body-weight reduction versus approximately 14% with semaglutide 2.4 mg over 72 weeks. Comparative cardiometabolic data show superior glycaemic control and lipid remodelling with dual agonism. Cardiovascular event data remain largely observational and directionally mixed in 2026.

As of 2026, two approved passive immunotherapies — lecanemab and donanemab — demonstrate statistically significant but modest slowing of cognitive decline in early Alzheimer's disease: 27% and 35% respectively on primary clinical scales versus placebo. Effect sizes are real but incremental, confined to amyloid-confirmed early-stage disease, and accompanied by clinically significant ARIA rates that constrain patient selection.

Two 2025–2026 studies — a 32-week RCT in adults with HIV-associated lipohypertrophy and a 24-week pilot in MASLD patients — both detected semaglutide's anti-aging signal primarily through DunedinPACE, a pace-of-aging clock built from longitudinal physiological data. Its structural design makes it uniquely sensitive to short-duration interventions, explaining a ~9% deceleration where cross-sectional age-estimate clocks showed weaker effects.

In the SELECT trial — a double-blind RCT of 17,604 non-diabetic adults with obesity or overweight and established cardiovascular disease — semaglutide 2·4 mg once weekly reduced the 3-point MACE composite (cardiovascular death, nonfatal MI, nonfatal stroke) by 20% over a mean 40-month follow-up (HR 0·80; 95% CI 0·72–0·90; p<0·001).

A 2025–2026 randomized, double-blind, placebo-controlled trial (NCT04019197, n=84) published in Nature Communications provides the first RCT evidence that once-weekly semaglutide measurably slows biological aging in humans. Across multiple DNA methylation clocks—including DunedinPACE, GrimAge, and PhenoAge—semaglutide-treated participants showed approximately 9% deceleration in the pace of aging versus placebo, with the strongest signals in inflammation-, brain-, and heart-linked organ-system clocks.